Originally developed by Amgen in conjunction with clinical studies in support of palifermin, the OMWQ is a reliable, valid, and responsive patient-reported measure of oral mucositis severity. While multiple variants of the OMDQ/OMWQ have been published, the version licensed by FACIT.org is the official, final version developed by Amgen.
Oral Mucositis Weekly Questionniare (OMWQ)
NUMBER OF ITEMS:
Oral mucositis patients 18 years and older
Paper and electronic
Self-administration and interview when applicable
TIME FOR COMPLETION:
Available translations of the OMWQ can be obtained when licensing the measure. Users are not permitted to translate the OMWQ without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the OMWQ.
Please contact us for more information.
Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.
Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.
To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.
Stiff PJ, Erder H, Bensinger WI, Emmanouilides C, Gentile T, Isitt J, Lu ZJ, Spielberger R. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006 Feb;37(4):393-401. doi: 10.1038/sj.bmt.1705250. PMID: 16415901.